- In the past few days, Wall Street analysts have projected that ResMed will report quarterly earnings of $2.90 per share on US$1.46 billion in revenue, implying year-over-year growth in both profit and sales.
- These projections also highlight expected expansion in key segments such as Total Sleep and Breathing Health and Residential Care Software, which together underpin analysts’ more optimistic view of ResMed’s near-term performance.
- Next, we’ll examine how these higher earnings and revenue expectations, particularly in Sleep and Breathing Health, may influence ResMed’s broader investment narrative.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research
ResMed Investment Narrative Recap
To own ResMed, you need to believe in sustained demand for sleep and breathing care and the company’s ability to pair devices with software and data. The latest analyst projections of US$2.90 EPS on US$1.46 billion in revenue reinforce Sleep and Breathing Health as the key near term catalyst, but do not materially change the biggest risk right now: potential pricing and reimbursement pressure if payers tighten funding or competitive bidding returns in a more aggressive form.
Against this backdrop, ResMed’s April 2026 results, with Q3 sales of US$1,431.41 million and basic EPS of US$2.74, are an important reference point. They show how the business was performing just before analysts lifted their near term expectations for Total Sleep and Breathing Health and Residential Care Software, and they frame how any upcoming earnings surprise could either bolster or weaken confidence in these segments as the main driver of the story.
Yet even with upbeat earnings projections, investors should be aware of the risk that reimbursement shifts or payer behavior could
Read the full narrative on ResMed (it’s free!)
ResMed’s narrative projects $6.5 billion revenue and $1.8 billion earnings by 2029
Uncover how ResMed’s forecasts yield a $247.93 fair value, a 11% upside to its current price
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming ResMed could reach about US$6.8 billion in revenue and US$1.8 billion in earnings by 2029, so this new earnings news may either reinforce their view or force a rethink, especially if reimbursement or funding constraints on higher priced products start to bite more quickly than expected
Explore 5 other fair value estimates on ResMed – why the stock might be worth just $224.10!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own
- A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate ResMed’s overall financial health at a glance.
Seeking Other Investments?
The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:
- We’ve uncovered the 8 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
- Uncover the next big thing with 19 elite penny stocks that balance risk and reward.
- The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NYSE:RMD
ResMed
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally
See The Free Research Report
Flawless balance sheet with solid track record and pays a dividend
See The Free Research Report
Similar Companies
NYSE:ABT
Abbott Laboratories
NYSE:MDT
Medtronic
Market Insights
What does frontier-beating open source mean for AI investors?
Andrew Legget
Why 2026’s worst-looking sector might be its most misread
Mitchell Lawler
A brand’s strength doesn’t always last
Richard Bowman
Weekly Picks
CE
Ceazaron Sparc AI4 months ago
When GPS fails: this small cap is fixing a $54B drone problem
Fair Value:CA$5.2535.8% undervalued
144followersusers have followed this narrative
0commentsusers have commented on this narrative
26likesusers have liked this narrative
HA
HarishPKon Amdocsabout 1 month ago
Why Amdocs is a high conviction Buy for me?
Fair Value:US$82.0332.6% undervalued
29followersusers have followed this narrative
3commentsusers have commented on this narrative
10likesusers have liked this narrative
IV
Ivoedon SBM Offshoreabout 1 month ago
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog
Fair Value:€44.529.5% undervalued
13followersusers have followed this narrative
0commentsusers have commented on this narrative
4likesusers have liked this narrative
CL
Clive_Thompsonon Green Tea Group9 days ago
One of China’s Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Fair Value:HK$8.726.3% undervalued
37followersusers have followed this narrative
3commentsusers have commented on this narrative
18likesusers have liked this narrative
RecentlyUpdated Narratives
TI
TickerTickleon Figmaabout 8 hours ago
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Fair Value:US$22.36
62followersusers have followed this narrative
7commentsusers have commented on this narrative
0likesusers have liked this narrative
JO
John_Ericon MercadoLibreabout 10 hours ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$7.31k73.7% undervalued
23followersusers have followed this narrative
0commentsusers have commented on this narrative
0likesusers have liked this narrative
DZ
Dzitkowskikon Diagnostykaabout 13 hours ago
Diagnostyka SA: Solidny lider, który już nie jest tani
Fair Value:zł163.28
1followerusers have followed this narrative
0commentsusers have commented on this narrative
0likesusers have liked this narrative
